Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis.

Imel EA, Starzyk K, Gliklich R, Weiss RJ, Wang Y, Williams SA

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA21 Jul 2020Cited by 2 (Europe PMC)

PMID32696118PMCIDPMC7661401DOI10.1007/s00198-020-05388-yPepBankPUB-32696118

Read at source PubMedAsk about this study

Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study13

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone13

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among treatment initiators, teriparatide patients had a lower mean age than denosumab patients.
In plain wordsPatients starting teriparatide had a lower average age than patients starting denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseAge at initiation
Study
n = 125,928
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Mean age
68.6 years
teriparatide
Mean age
72.1 years
denosumab
Source sentences
Summary
Mean age (standard deviation) was 69.2 (10.6) years for the ABL cohort, 68.6 (11.3) for TPTD, and 72.1 (10.2) for DMAB (P < 0.001; ABL vs DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3269611802
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among treatment initiators, previous pathologic or fragility fracture was more frequent with teriparatide than denosumab.
In plain wordsPatients starting teriparatide more often had a previous fragility fracture than patients starting denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePrevious fragility fracture
Study
n = 125,928
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Previous fracture
18.8%
teriparatide
Previous fracture
9.6%
denosumab
Source sentences
Summary
Nearly twice as many patients initiating ABL (19.1%) and TPTD (18.8%) had a previous pathologic/fragility fracture vs DMAB (9.6%; P < 0.001 ABL vs DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3269611807
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among treatment initiators, fewer teriparatide patients had Charlson comorbidity index ≥2 than denosumab patients.
In plain wordsPatients starting teriparatide less often had a Charlson comorbidity index ≥2 than patients starting denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCharlson comorbidity index ≥2
Study
n = 125,928
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Index ≥2
39.7%
teriparatide
Index ≥2
48.4%
denosumab
Source sentences
Summary
Fewer patients initiating ABL (36.3%) or TPTD (39.7%) had Charlson comorbidity index of ≥ 2 vs DMAB (48.4%; P < 0.001 ABL vs DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3269611809
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among treatment initiators, prior bisphosphonate use was more common with teriparatide than denosumab.
In plain wordsPatients starting teriparatide more often had previous bisphosphonate use than patients starting denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePrior bisphosphonate use
Study
n = 125,928
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Prior bisphosphonate use
19.6%
teriparatide
Prior bisphosphonate use
16.6%
denosumab
Source sentences
Summary
Bisphosphonate use was more common before initiating ABL (19.2%) or TPTD (19.6%), than before initiating DMAB (16.6%; P < 0.001 ABL vs DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3269611813
05HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among treatment initiators, abaloparatide patients were younger than denosumab patients.
In plain wordsPatients starting abaloparatide were younger than patients starting denosumab.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseAge at initiation
Study
n = 119,384
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Mean age
69.2 years
abaloparatide
Mean age
72.1 years
denosumab
Source sentences
Summary
Mean age (standard deviation) was 69.2 (10.6) years for the ABL cohort, 68.6 (11.3) for TPTD, and 72.1 (10.2) for DMAB (P < 0.001; ABL vs DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3269611801
06HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among treatment initiators, the female proportion was higher with abaloparatide than denosumab.
In plain wordsWomen formed a larger share of patients starting abaloparatide than denosumab.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemale proportion
Study
n = 119,384
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Female proportion
95.2%
abaloparatide
Female proportion
91.3%
denosumab
Source sentences
Summary
Proportionally more patients initiating ABL were female (95.2% ABL, 86.9% TPTD, and 91.3% DMAB, P < 0.001 ABL vs TPTD or DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3269611803
07HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among treatment initiators, previous pathologic or fragility fracture was more frequent with abaloparatide than denosumab.
In plain wordsPatients starting abaloparatide more often had a previous fragility fracture than patients starting denosumab.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreasePrevious fragility fracture
Study
n = 119,384
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Previous fracture
19.1%
abaloparatide
Previous fracture
9.6%
denosumab
Source sentences
Summary
Nearly twice as many patients initiating ABL (19.1%) and TPTD (18.8%) had a previous pathologic/fragility fracture vs DMAB (9.6%; P < 0.001 ABL vs DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3269611806
08HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among treatment initiators, fewer abaloparatide patients had Charlson comorbidity index ≥2 than denosumab patients.
In plain wordsPatients starting abaloparatide less often had a Charlson comorbidity index ≥2 than patients starting denosumab.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseCharlson comorbidity index ≥2
Study
n = 119,384
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Index ≥2
36.3%
abaloparatide
Index ≥2
48.4%
denosumab
Source sentences
Summary
Fewer patients initiating ABL (36.3%) or TPTD (39.7%) had Charlson comorbidity index of ≥ 2 vs DMAB (48.4%; P < 0.001 ABL vs DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3269611808
09HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among treatment initiators, prior bisphosphonate use was more common with abaloparatide than denosumab.
In plain wordsPatients starting abaloparatide more often had previous bisphosphonate use than patients starting denosumab.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreasePrior bisphosphonate use
Study
n = 119,384
Comparator
denosumab initiators
Outcome group
Patterns of use · Whole body
Measurements
Prior bisphosphonate use
19.2%
abaloparatide
Prior bisphosphonate use
16.6%
denosumab
Source sentences
Summary
Bisphosphonate use was more common before initiating ABL (19.2%) or TPTD (19.6%), than before initiating DMAB (16.6%; P < 0.001 ABL vs DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3269611812
10HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among treatment initiators, the female proportion was higher with abaloparatide than teriparatide.
In plain wordsWomen formed a larger share of patients starting abaloparatide than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemale proportion
Study
n = 11,876
Comparator
teriparatide initiators
Outcome group
Patterns of use · Whole body
Measurements
Female proportion
95.2%
abaloparatide
Female proportion
86.9%
teriparatide
Source sentences
Summary
Proportionally more patients initiating ABL were female (95.2% ABL, 86.9% TPTD, and 91.3% DMAB, P < 0.001 ABL vs TPTD or DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3269611804
11HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among treatment initiators, the female proportion was lower with teriparatide than abaloparatide.
In plain wordsWomen formed a smaller share of patients starting teriparatide than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFemale proportion
Study
n = 11,876
Comparator
abaloparatide initiators
Outcome group
Patterns of use · Whole body
Measurements
Female proportion
86.9%
teriparatide
Female proportion
95.2%
abaloparatide
Source sentences
Summary
Proportionally more patients initiating ABL were female (95.2% ABL, 86.9% TPTD, and 91.3% DMAB, P < 0.001 ABL vs TPTD or DMAB).
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3269611805
12HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among teriparatide initiators, 33.8% had prior osteoporosis treatment.
In plain wordsAmong patients starting teriparatide, 33.8% had previous osteoporosis treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePrior osteoporosis treatment
Study
n = 9,210
Outcome group
Patterns of use · Whole body
Measurements
Prior osteoporosis treatment
33.8%
teriparatide initiators
Source sentences
Summary
Before initiating ABL, TPTD, or DMAB, 44.3%, 33.8%, and 33.9% of patients had prior osteoporosis treatment, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3269611811
13HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among abaloparatide initiators, 44.3% had prior osteoporosis treatment.
In plain wordsAmong patients starting abaloparatide, 44.3% had previous osteoporosis treatment.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicablePrior osteoporosis treatment
Study
n = 2,666
Outcome group
Patterns of use · Whole body
Measurements
Prior osteoporosis treatment
44.3%
abaloparatide initiators
Source sentences
Summary
Before initiating ABL, TPTD, or DMAB, 44.3%, 33.8%, and 33.9% of patients had prior osteoporosis treatment, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3269611810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.